ORTHOReBIRTH USA Signs Letter Of Intent With Dr. Loubert S. Suddaby
New and innovative products will be developed, in order to further transform the biologic market
GEORGETOWN, Texas, Nov. 1, 2018 /PRNewswire-PRWeb/ -- ORTHOReBIRTH USA has signed a letter of intent to develop new and innovative biologic products with Dr. Loubert S. Suddaby, a neurosurgeon practicing in Buffalo, New York.
"Dr. Suddaby's work has put him at the forefront of the neurosurgical field," says Doris Blake, president and COO of ORTHOReBIRTH USA. "We are excited to collaborate with him and to continue transforming today's biologic industry."
ORTHOReBIRTH USA brings to market and produces premium orthopedic biologics, such as ReBOSSIS®, which is the only biosynthetic scaffold with electrospun microfiber construction. This letter of intent will lead to more exciting products within this field.
About ORTHOReBIRTH USA
We recognize the challenges associated with orthopedic surgery—for patients, surgeons and hospitals alike. We are committed to bringing to market cutting-edge orthopedic biologics that improve patients' quality of life and offer superior outcomes. We have carried out extensive studies on what makes biologic materials successful and have used that knowledge to engineer world-class products for use in a host of orthopedic surgical procedures. ORTHOReBIRTH USA is proud to bring premium orthopedic biologics, such as ReBOSSIS®, to surgeons practicing around the world.
SOURCE ORTHOReBIRTH USA
Share this article